Bernhard C Pestalozzi
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
Pestalozzi B, Novak U, Nussbaum C, Seifert B, Bigler M, Bize V, Vilei S, Rageth C, Aebi S, Borner M, Buser K, Tausch C, Dedes K, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A. Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). BMC cancer 2017; 17:265.
13.04.2017Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
13.04.2017BMC cancer 2017; 17:265
Pestalozzi Bernhard C, Novak Urban, Nussbaum Catrina Uhlmann, Seifert Bettina, Bigler Martin, Bize Vincent, Vilei Simona Berardi, Rageth Christoph, Aebi Stefan, Borner Markus, Buser Katharina, Tausch Christoph, Dedes Konstantin J, Rochlitz Christoph, Zimmermann Stefan, von Moos Roger, Winterhalder Ralph, Ruhstaller Thomas, Mueller Andreas
Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation
Samaras P, Renner C, Knuth A, Stahel R, Stussi G, Schanz U, Pestalozzi B, Honegger H, Mischo A, Petrausch U, Haile S, Siciliano R, Buset E, Stenner-Liewen F. Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation. Oncology 2010; 79:93-97.
15.11.2010Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation
15.11.2010Oncology 2010; 79:93-97
Samaras Panagiotis, Renner Christoph, Knuth Alexander, Stahel Rolf A, Stussi Georg, Schanz Urs, Pestalozzi Bernhard C, Honegger Hanspeter, Mischo Axel, Petrausch Ulf, Haile Sarah, Siciliano Raffaele Daniele, Buset Elefteri M, Stenner-Liewen Frank
Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract
Riener M, Vogetseder A, Pestalozzi B, Clavien P, Probst-Hensch N, Kristiansen G, Jochum W. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract. Hum Pathol 2010; 41:1558-65.
01.11.2010Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract
01.11.2010Hum Pathol 2010; 41:1558-65
Riener Marc-Oliver, Vogetseder Alexander, Pestalozzi Bernhard C, Clavien Pierre-Alain, Probst-Hensch Nicole, Kristiansen Glen, Jochum Wolfram
Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas
Riener M, Moch H, Soltermann A, Jochum W, Clavien P, Probst-Hensch N, Pestalozzi B, Soll C, Fritzsche F, Kristiansen G. Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. Histopathology 2010; 56:600-6.
01.04.2010Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas
01.04.2010Histopathology 2010; 56:600-6
Riener Marc-Oliver, Moch Holger, Soltermann Alex, Jochum Wolfram, Clavien Pierre-Alain, Probst-Hensch Nicole, Pestalozzi Bernhard C, Soll Christopher, Fritzsche Florian R, Kristiansen Glen
Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02)
Klaeser B, Ruhstaller T, von Moos R, Albrecht S, Caspar C, Pestalozzi B, Zünd M, Brauchli P, Cescato-Wenger C, Hany T, Balmer-Majno S, Widmer L, Köberle D, Schuller J, Nitzsche E, Lange J. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie 2009; 32:724-30.
01.12.2009Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02)
01.12.2009Onkologie 2009; 32:724-30
Klaeser Bernd, Ruhstaller Thomas, von Moos Roger, Albrecht Susanne, Caspar Clemens, Pestalozzi Bernhard C, Zünd Michael, Brauchli Peter, Cescato-Wenger Corinne, Hany Thomas, Balmer-Majno Sabine, Widmer Lucas, Köberle Dieter, Schuller Jan C, Nitzsche Egbert, Lange Jochen
IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas
Riener M, Fritzsche F, Clavien P, Pestalozzi B, Probst-Hensch N, Jochum W, Kristiansen G. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Human pathology 2009; 40:1377-83.
01.10.2009IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas
01.10.2009Human pathology 2009; 40:1377-83
Riener Marc-Oliver, Fritzsche Florian R, Clavien Pierre-Alain, Pestalozzi Bernhard C, Probst-Hensch Nicole, Jochum Wolfram, Kristiansen Glen
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
Bernhard J, Pestalozzi B, Köhne C, Mingrone W, Stemmer S, Tàmas K, Kornek G, Koeberle D, Herrmann R, Figer A, Bauer J, Saletti P, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3695-701.
01.08.2008Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
01.08.2008Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3695-701
Bernhard Jürg, Pestalozzi Bernhard C, Köhne Claus-Henning, Mingrone Walter, Stemmer Salomon M, Tàmas Karin, Kornek Gabriela V, Koeberle Dieter, Herrmann Richard, Figer Arie, Bauer Jean, Saletti Piercarlo, Dietrich Daniel, Scheithauer Werner, Gerber Daniela, Bodoky György, Ruhstaller Thomas, Glimelius Bengt, Bajetta Emilio, Schüller Johannes, Central European Cooperative Oncology Group
Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials
Pestalozzi B, Goldhirsch A, Coates A, Castiglione-Gertsch M, Viale G, Murray E, Thürlimann B, Snyder R, Lindtner J, Holmberg S, Gelber R, Price K, Gusterson B, Mallon E, Zahrieh D, International Breast Cancer Study Group. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. JCO 2008; 26:3006-14.
20.06.2008Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials
20.06.2008JCO 2008; 26:3006-14
Pestalozzi Bernhard C, Goldhirsch Aron, Coates Alan S, Castiglione-Gertsch Monica, Viale Giuseppe, Murray Elizabeth, Thürlimann Beat, Snyder Raymond, Lindtner Jurij, Holmberg Stig B, Gelber Richard D, Price Karen N, Gusterson Barry A, Mallon Elizabeth, Zahrieh David, International Breast Cancer Study Group
Gemcitabine-associated hemolytic-uremic syndrome
Walter R, Jörger M, Pestalozzi B. Gemcitabine-associated hemolytic-uremic syndrome. American journal of kidney diseases : the official journal of the National Kidney Foundation 2002; 40:E16.
01.10.2002Gemcitabine-associated hemolytic-uremic syndrome
01.10.2002American journal of kidney diseases : the official journal of the National Kidney Foundation 2002; 40:E16
Walter Roland B, Jörger Markus, Pestalozzi Bernhard C
Gemcitabine-related pulmonary toxicity
Jörger M, Gunz A, Speich R, Pestalozzi B. Gemcitabine-related pulmonary toxicity. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2002; 132:17-20.
12.01.2002Gemcitabine-related pulmonary toxicity
12.01.2002Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2002; 132:17-20
Jörger Markus, Gunz A, Speich R, Pestalozzi Bernhard C